TTC22

Across TCGA pan-cancer cohorts, TTC22 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of TTC22’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TTC22 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TTC22 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where TTC22 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTC22 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.855	<.001	11	view →
LUAD	Female	III,IV	+0.538	.032	1	view →
LSCC	Female	III,IV	+0.470	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

TTC22–HNSC

Open the HNSC breakdown →